Streetbeat News

Equity Actions

DECA

Denali Capital Acquisition Corp. has announced an extension of the deadline to complete its business combination from May 11 to June 11. This extension provides additional time for Denali Capital Acquisition Corp. to finalize its business combination plans.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 8:38 pm

BECN

Beacon (BECN) has initiated an additional $225 million accelerated share buyback agreement. This move is part of the company's ongoing efforts to enhance shareholder value and reflects its confidence in the long-term prospects of the business.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 8:36 pm

MACK

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) announced the approval of a Plan of Dissolution by its stockholders and declared a liquidating cash dividend of $15.10 per share, to be paid on May 17, 2024. The company's stock will continue to trade on NASDAQ until May 17, 2024, and will be delisted on May 20, 2024. Future distributions are possible if reserved amounts are deemed unnecessary or if additional milestones under existing agreements are achieved.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 8:36 pm

AUVI

Applied UV (AUVI) announced the resignation of Brian Stern and Dallas Hack as board members, and Eugene Burleson as Chairman of the Board.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 8:35 pm

DECA

Denali Capital Acquisition Corp. (DECA) has extended the deadline to complete its business combination from May 11, 2024, to June 11, 2024. This extension provides additional time for DECA to finalize its business combination plans.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 8:35 pm

REPX

Riley Exploration Permian, Inc. has filed for a mixed shelf offering of up to $250 million, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 8:32 pm

NEPH

Nephros has filed for a mixed shelf offering with the SEC, allowing it to issue up to $50M in securities. This strategic move could provide the company with flexible financing options for future growth, acquisitions, or debt management. Investors should monitor how Nephros plans to utilize these funds, as it could significantly impact its financial health and growth trajectory.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 8:31 pm

SKYE

Skye Bioscience Inc has filed for a mixed shelf offering of up to $300 million, according to a recent SEC filing.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 8:31 pm

DARE

Dare Bioscience has filed with the SEC to offer up to $18.1 million in common stock. This move indicates the company's strategy to raise capital, potentially diluting current shareholders but providing funds for operations or expansion.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 8:31 pm

CTCX

Carmell Therapeutics has filed with the SEC for the resale of up to 1.3 million common shares by the selling stockholders. This move indicates a potential increase in the company's public float, which could have various impacts on its stock price.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 8:31 pm